Small Cap Feast

4th April 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: 
Ocean Harvest Technology Group plc (OHT), a producer of animal feed additives from multispecies seaweed blends joins AIM. Based on the placing price of 16p, the market capitalisation of the Company will be approximately £20m at Admission. Placing raised gross proceeds of £6m.

Leavers:
No leavers today.



What’s Cooking In The IPO Kitchen?

Beacon Energy plc, intends to join the AIM market. In accordance with the Company's strategy to focus on growth through acquisition or farm-in to oil and gas projects, the Company entered into the SPA with Tulip Oil Holdings B.V. In conjunction with the Acquisition, the Company has conditionally raised total gross proceeds of £6.04m and will be used to fund the drilling of the SCHB-2 development well onshore Germany and for working capital. Expected admission date is 11 April 2023.

M7 Box+ REIT plc, a newly established, externally managed closed-ended investment company announces that it intends to join the Wholesale segment of IPSX. Upon Admission, the Company proposes to acquire a portfolio of seven let and operational e-warehouses from M7 Box+ II LP. As at 31 December 2022, the Property Portfolio was valued at £228.9m. Expected Admission April 2023.

Fadel Partners, a developer of cloud based brand compliance and rights and royalty management software, working with some of the world's leading licensors and licensees across media, entertainment, publishing, consumer brands and hi-tech & gaming companies intends to join the AIM market. FADEL has two solutions, being IPM Suite and Brand Vision. Expected capital raise on Admission of £7.5m and Market Capitalisation of £28.8m. Expected Admission 6 April 2023.


Breakfast Buffet

ATOME Energy 95p £34.2m (ATOM.L)
The international green hydrogen and ammonia production, announces its 75% owned Icelandic subsidiary, Green Fuel ehf, has entered into a non-binding term sheet with HS Orka, a leading producer of renewable energy in Iceland, for the supply of up to 40MW from geothermal and hydroelectric power with the intention for both parties to enter a binding Power Purchase Agreement, subject to conditions, prior to year-end 2023. The power is due to be delivered for the start of Green Fuel's commercial operation, scheduled in 2026. In addition to the 40MW from HS Orka, Green Fuel has also signed a Letter of Intent with ON Power, another company generating power from the same sources in the country, for the supply of up to 20MW of renewable power which is expected to be available from 2027.

Destiny Pharma 30p £28.3m (DEST.L)
A clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, to successfully colonise the gut following administration of fidaxomicin has been peer-reviewed and published in Microbiology Spectrum. The paper concludes that NTCD-M3 is able to effectively and fully colonise the gut following fidaxomicin administration, indicating that NTCD-M3 would be effective in patients receiving this antibiotic, as well as older antibiotics, such as vancomycin and metronidazole.

Epwin Group 72.5p £105.1m (EPWN.L)
A manufacturer of energy efficient and low maintenance building products, supplying the Repair, Maintenance and Improvement, new build and social housing sectors, announces its full year results for the year ended 31 December 2022. Record revenues increased 8% to £355.8m and underlying operating profit increased by 16% to £21.5m. Covenant net debt at year end of £17.9m (2021: £9.4m), following a net acquisition cash consideration of £17.8m in 2022. Management has proposed final dividend of 2.55 pence per share, resulting in a total dividend for 2022 of 4.45 pence per share (2021: 4.10 pence per share. Current trading is in line with the Board's expectations.

FD Technologies £17.38 £487.8m (FDP.L)
A group of data-driven businesses announces a trading update for the year ended 28 February 2023 (full year results expected 23 May 2023). Group revenue is expected to be c.£296m, an increase of 12%. Group EBITDA is expected to be c.£35m, with strong performances at KX and First Derivative offset by a weak demand environment at MRP. KX and First Derivative have performed strongly, with both revenue and EBITDA ahead of expectations. In FY24 management expects KX to achieve ARR growth of at least 35% and First Derivative EBITDA to deliver further improvements.

Gooch & Housego 447p £111.9m (GHH.L)
The specialist manufacturer of photonic components & systems, provides an update on trading for the six months ended 31 March 2023. Revenue is expected c.£71.0m (31 March 2022: £54.1m) supported by favourable exchange rate movements and the effects of price increases to offset cost input inflation. Output levels have increased and trading is expected to be more evenly weighted between the two halves of the financial year. As at 31 March 2023 the order book stood at £124.4m (31 March 2022: £119.9m), an increase of 3.8%, or a reduction of 0.1% at constant currency, compared with the same time last year. Net debt c.£19m and the Group had $46.2m available from existing committed and uncommitted debt facilities to fund its future growth activities. Trading is in line with current expectations.

Kooth 235p £77.7m (KOO.L)
A UK digital mental health platform, announces audited results for the twelve months ended 31 December 2022. Revenues increased 21% to £20.1m (2021: £16.7m), while Annual Recurring Revenue increased 25% to £21.1m (2021: £16.9m). 95% of revenues came from contracts of 12 months or longer. Adjusted EBITDA of £1.6m (2021: £2.1m), partly as a result of investment in the US. Throughout the period Kooth signed its first US contract, a $3m pilot contract in the State of Pennsylvania and post period end, Kooth was Selected for significant contract in California to support all 13-25 year olds. Net cash of £8.5m at year end (2021: £7.1m) and no debt.

Marula Mining 12.12p £12.10m (AQSE:MARU)
An African focused mining and development company, provides an update on its Nyorinyori Graphite Project, which the Company has a 75% interest, located in the Simanjiro District, in the Manyara Region of Tanzania. A technical site visit was completed, during which high-grade graphite mineralisation, with visual estimates of +90% graphite content in shallow and broad graphite veins were exposed at depths of approximately 2 metres from limited and small scale mining activities. Visual observations of the high-grade graphite mineralization, has identified jumbo graphite flakes present throughout. The Company has now committed to an accelerated exploration program at Nyorinyori which will include further mapping, sampling and a maiden shallow drilling program. Negotiations have also commenced with Takela to potentially increase the scope of the Project to include up to 25 additional granted mining licenses.

Physiomics* 2.8p £2.7m (PYC.L)
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, provides a trading update. Revenues have come under pressure at least partly as a result of the ongoing squeeze in biotech funding which is causing companies of all sizes to conserve cash. Restructuring within key client, Merck has led to a number of anticipated projects not being commissioned within the current financial year which will lead to a shortfall in revenue compared to that budgeted for this client. The pipeline remains strong, with over 25 potential largely new client projects in discussion at various stages. As a result, the Company believes its total income for the current financial year will be around £750k. The company will make a live presentation on this update via Investor Meet Company on 6 April 2023 at 3:00pm BST https://www.investormeetcompany.com/physiomics-plc/register-investor.

Proteome Sciences 4.06p £12m (PRM.L)
The protein biomarker research and development Company, announces its audited results for the year ended 31 December 2022. Group revenues increased by 52% to £7.78m (2021: £5.13m), services revenue increased 45% to £2.75m (2021: £1.90m) and sales, royalties and milestones attributable to TMT®/TMTpro™ reagents increased by 56% to £5.03m (2021: £3.23m). EBITDA of £2.13m increased by £1.50m or 239% on prior year mainly due to increased revenues and including the sales milestone payment of £0.87m received from Thermo Scientific. The Company reported an increased operating profit of £1.73m (2021: £0.41m) and a profit after tax of £1.33m (2021: £0.07m). Cash reserves at 31 December 2022 of £3.99m (2021: £2.39m).

Ramsden Holdings 230p £72.8m (RFX.L)
The diversified financial services provider and retailer, announces a pre-close trading update for the six months ended 31 March 2023. Ramsdens has made progress across each of its four key business segments as well as against the Group's broader long-term strategic objectives. As a result, the Board now expects the FY23 Profit before Tax to be not less than £9.5m (FY22: £8.3m). Jewellery retail gross profit increased by over 20% on the prior year; foreign currency exchange was up by approximately 40%; The pawnbroking loan book has increased by 13% and the purchase of precious metal volumes has increased by over 20%. The total store estate at the Period end was 158 stores, excluding two franchised stores, (H1 FY22: 153 stores).

4 April 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram